Objective To assess the effects of a soybean lipid emulsion infusions on levels of unbound (free) bilirubin (Bf) and unbound free fatty acids (FFAu) as well as changes in Bf and total serum bilirubin (TSB) during phototherapy in infants born preterm.
M ore than 80% of infants develop some degree of hyperbilirubinemia during the first week of life. 1 Although the effects of jaundice typically are benign in infants born full term, infants born preterm are at increased risk for bilirubin encephalopathy. 2, 3 Currently total serum bilirubin (TSB) levels are used as indicators for treatment with phototherapy to prevent progression to toxic levels. Levels of free, unbound bilirubin, however, predict the risk of bilirubin neurotoxicity more accurately than TSB. [4] [5] [6] Levels of free unbound bilirubin can be elevated relative to TSB by displacement of bilirubin from albumin binding sites by a variety of compounds including unbound free fatty acids (FFAu). Free unbound bilirubin crosses the blood-brain barrier and exerts its toxic effect. Direct determination of free bilirubin (Bf) may be important in assessing the toxicity risk of bilirubin and targeting therapy. Unfortunately, it is not measured routinely in the US because of lack of commercially available assay methods but is available in other countries, such as Japan. 7, 8 Most infants born with very low birth weight are treated with parenteral nutrition, including lipid infusions. Intralipid is an emulsion of soybean oil that is a major source of calories and essential fatty acids. Similar to bilirubin, serum free fatty acids are bound primarily to albumin in the circulation but are in equilibrium with a small unbound fraction that exerts biologic effects. A concern about the use of intralipid is that elevated levels of FFAu can displace bilirubin from albumin binding sites, resulting in increased Bf levels relative to TSB. 9, 10 This effect may be more apparent in infants born very preterm because of lower albumin binding capacity for bilirubin. 11 We have shown previously that both FFAu and Bf were highly elevated in infants with extremely low birth weight treated with intralipid at 3 g/kg/d. 12 In the present study, we hypothesized that (1) increasing doses of intralipid (from 1 to 3 g/kg/ d) would be associated with increasing levels of FFAu and Bf, independent of TSB and (2) that phototherapy would be effective in lowering TSB but not Bf, particularly in infants born extremely preterm (<28 weeks of gestational age) during intralipid infusion. Because the laboratory policy is to store all blood samples for 7 days, it was possible to obtain research samples earlier than the age of the infant at consent. The administration of intralipid was determined by the clinical team, usually commencing at a dose of 1 g/kg/d on the second day of life and advancing it daily to a maximum of 3 g/kg/d. The decision to withhold, reduce, or terminate the lipid infusion was determined by the clinical staff and resulted in some infants receiving fewer than the projected doses. The decision to initiate and terminate phototherapy was determined by the clinical staff and based on published recommendations. 13 Phototherapy devices used were neoBLUE LED (Natus Medical Inc, Pleasanton, California) positioned above the infants for those in incubators and fluorescent bulbs housed in the phototherapy attachment for those infants in warmer beds. Irradiance levels ranged between 15 and 30 mw/cm 2 /nm.
Blood Sampling
Plasma samples were obtained before intralipid infusion (intralipid 0), during infusion of 1, 2, and 3 g/kg/d (intralipid 1, intralipid 2, intralipid 3), and before and after phototherapy. Samples were obtained from residual blood drawn for clinical indications during those intralipid dosing windows. These samples were collected immediately after completion of the requested clinical test, processed, and frozen. The lack of ordered clinical samples or inadequate residuals resulted in an incomplete set of research samples for some infants. Deidentified samples were stored at −70°C and shipped to Fluoresprobe Sciences for determination of Bf and FFAu.
Bf, FFAu and TSB Measurements
FFAu and Bf were measured in the same plasma sample with the use of fluorescently labeled mutants of fatty acid binding proteins. [14] [15] [16] The Bf probe (BL22P1B11-Rh) binds unconjugated bilirubin with high affinity (bilirubin-albumin equilibrium dissociation constant [Kd] = 16 nM) but is poorly sensitive to FFA (Kd > 3000 nM), conjugated bilirubin (Kd > 300 nM), bilirubin photoisomers, bilirubin oxidation products, ibuprofen, and indomethacin.
14 FFAu concentrations were determined with the ADIFAB2 probe (FFA Sciences LLC, San Diego, California). 12, 15 Fluorescence was assessed at 2 emission wavelengths: 457 and 550 nm for the FFAu probe and 525 and 580 nm for the Bf probe (excitation = 375 nm for both). The ratio of fluorescence at the 2 wavelengths, together with probe characteristics, yielded the FFAu and Bf concentrations. Fluorescence was measured at 22°C by the use of handheld ratio fluorometers in which plasma sample volumes were 4 mL for FFAu and 25 mL for Bf measurements. After dilution, the total volume was 200 mL so that FFAu was measured at 50-fold and Bf at 8-fold dilution of the plasma sample. 14, 15 The accuracy of the Bf probe measurements was confirmed previously by comparison with the peroxidase assay in adult plasma supplemented with bilirubin as well as in bilirubin-albumin in vitro measurements. 14 The Bf probe has an average coefficient of variation of 3% for repeated measurements of aqueous bilirubin, bilirubin-albumin complexes, and bilirubin-spiked adult plasma over a Bf range from 1 to >350 nmol/L.
14 Measurements with the Bf probe, in contrast to the peroxidase method, determine the Bf concentration directly in a single measurement and are insensitive to substances that can interfere with the peroxidase measurement.
14 TSB was measured via the diazo method at the Robert Wood Johnson Medical School clinical laboratory. Plasma albumin was measured in infants before intralipid infusion by use of the bromocresol green albumin assay (Sigma-Aldrich, St Louis, Missouri) method, which was standardized with fatty acid free human serum albumin from 72 to 722 mM (coefficient of variation< 4%). Infant plasma (5 mL) was diluted into 200 mL of the bromocresol green reagent, and absorbance was measured at 620 nm. We calculated the Kd, which is the inverse of the binding constant Ka using equation,
where At is the measured albumin concentration and Kd is in mol/L or nM.
Statistical Analyses
Changes in TSB, Bf, and FFAu as a function of increasing dose of intralipid or of phototherapy were analyzed by repeated measures analysis and verified by the generalized estimating equation semiparametric regression method. Multiple regression analysis was performed to evaluate the correlation between FFAu and TSB with Bf with increasing dose of intralipid, taking into account confounding variables including birth weight, gestational age, sex, race, and 5-minute Apgar. The analysis was verified by nonparametric Spearman correlation. The analyses were performed with XLSTAT (AddinSoft, New York, New York) and verified with SAS Software (SAS Institute, Cary, North Carolina). P values < .05 were considered statistically significant.
Results

Effects of Increasing Dose of Intralipid on TSB, Bf, and FFAu
The study population included 97 infants with a mean birth weight of 1315 ± 435 g and gestational age of 29.2 ± 3.1 weeks. Fifty-two percent of infants were male. Fifty-two percent of the infants were white, 30% were black, 17% were Asian, and 1% were Hispanic. For 48 infants, measurements of Bf, FFAu, and TSB were obtained before the intralipid infusion (intralipid 0) and at all 3 intralipid dosages, intralipid 1, intralipid 2, and intralipid 3. Of the remaining infants, 32 had measurements at 3 of the 4 intralipid steps, 12 infants had measurements at 2 steps, and 5 had a measurement at a single step. Thus, the data are cross-sectional with reference to increasing doses of intralipid infusion.
The mean age at the start and advancement of intralipid infusion was 28.6 ± 11.5 (SD) (range 10-55) hours for intralipid 1, 47.9 ± 13.7 (range 13-79) hours for intralipid 2, and 77.6 ± 22.3 (range 37-200) hours for intralipid 3. The mean age at initiation of blood sampling was 13 ± 7 (range 0.5-41) hours for intralipid 0, 33 ± 12 (range 8-74) hours for intralipid 1, 61 ± 17 (range 22-104) hours for intralipid 2, and 110 ± 39 (range: 59-311) hours for intralipid 3. As shown in Figure 1 , TSB increased between intralipid 0 and intralipid 2, consistent with the age-dependent natural history of hyperbilirubinemia of prematurity. TSB decreased to 5.8 ± 2.0 mg/dL at intralipid 3, likely related to the use of phototherapy in most (n = 91) of the infants. Bf did not decrease at intralipid 3 despite the phototherapy-related reduction of TSB. The quadratic trend for TSB was significant (P < .001). FFAu and Bf increased significantly (P < .001) with each incremental increase in intralipid dose. It is notable that larger increases in free fatty acids and Bf occurred in infants of less than 28 weeks of gestation (Figure 2 ), but overall gestational age had little if any impact on the results of the study. This discrepancy may be due to the high variance of findings in the heavier infants, who constituted more (67%) of the overall group.
Bf was correlated tightly with TSB at doses of 0-1 g/kg/d of intralipid but not at greater intralipid doses of 2-3 g/kg/d (Figure 3 
equal to 28 weeks of gestational age and all (except one with birth weight 1505 g) weighed less than 1500 g at birth. Three infants had final Bf levels above 40 nM and were all <28 weeks of gestation and <1250 g birth weight. One infant of this group died, with no autopsy performed. Detailed auditory evaluations were not available for the 2 survivors. Bilirubin-albumin binding was highly variable among infants before intralipid infusion, with Kd values in 57 infants ranging from 15 to 75 nM. FFAu, but not bilirubin-albumin Kd, correlated with Bf levels at all intralipid infusion rates, suggesting that FFAu overpower any intrinsic differences in binding affinity.
Multiple linear regression was performed at each intralipid step on Bf with the following selected variables: TSB, FFAu, birth weight, gestational age, sex, race, and 5-minute Apgar score. The latter 3 variables did not have significant effects on the changes in Bf as a function of increasing dose of intralipid. At intralipid 0 and intralipid 1, only TSB contributed significantly, P < .05. At intralipid 2 and intralipid 3, both TSB and FFAu were significant, P < .05. Gestational age did not contribute significantly except at intralipid 1 (P < .05). At intralipid 2 and intralipid 3, Bf increased similarly for all gestational ages between 23 and 34 weeks (Figure 2) .
Effects of Phototherapy on TSB, Bf, and FFAu
Phototherapy was initiated in 91 infants at 41.5 ± 15.9 hours of age at a TSB level of 7.4 ± 2.2 mg/dL and discontinued at 80.3 ± 24.3 hours of age at a TSB level of 5.0 ± 1.9 mg/dL with an exposure duration of 39.0 ± 28.2 hours. The demographic characteristics of infants receiving phototherapy were similar to those of the entire group. For the entire group, TSB significantly decreased during the period of phototherapy. There was a slight but statistically significant decrease in Bf levels during phototherapy, but FFAu levels increased (Table I) . When the changes in these variables were assessed with reference to gestational age, more mature infants (>28 weeks) demonstrated decreased TSB and Bf with phototherapy similar to the total group, as well as greater FFAu associated with advances to greater doses of intralipid (2-3 g/kg/d) during phototherapy ( Table I ). In the less mature infants (<28 weeks), phototherapy significantly reduced the TSB but not Bf. FFAu also increased significantly because of greater intralipid intake. The effect of FFAu on Bf was more powerful than phototherapy, as Bf was reduced by phototherapy at low FFAu but increased at high FFAu levels ( Table II) . We compared the effects of FFAu levels above and below the median (25 nM) on the degree of phototherapy-mediated reduction of TSB and Bf. For FFAu levels ≥25 nM, TSB is reduced by 39% (P < .0001) but Bf increased by 15% (P = not significant). At FFAu < 25 nM, TSB decreases 31% (P < .0001) and Bf 24% (P < .0001).
Discussion
Increasing doses of intralipid result in a significant increase in FFAu and Bf levels in infants born preterm. This finding is consistent with the idea that intralipid increases FFAu to levels that can displace bilirubin from its binding sites on albumin or inhibit its binding. These findings highlight the role of bilirubin-albumin binding equilibrium in the determination of Bf. Before intralipid and at 1 g/kg/d dose of intralipid, bilirubin is bound tightly to albumin, so Bf correlates well with TSB ( Figure 3, A and B) . In contrast, at high doses of intralipid, Bf is not well-correlated with TSB because of competition for, or inhibition of, albumin binding by greater FFAu (Figure 3 , C and D). The strength of this effect is determined, in part, by the bilirubin-albumin binding constant, which we found to be variable widely between infants, consistent with previous reports. 4, 17 The high degree of variability in FFAu and bilirubin-albumin Kd likely reflects developmentally determined alterations in metabolism and accounts for large infantto-infant differences in Bf at specific doses of intralipid, as well as differences in the Bf in response to phototherapy in lower and higher gestational age ( Table I) .
Our findings are consistent with Amin et al, 10, 18 who reported previously that intralipid infusion in infants with extremely low birth weight (<28 weeks of gestation) results in increased FFA and Bf. In contrast to Amin et al, we also found intralipid-dependent increases in FFAu and Bf in infants with gestation ages between 28 and 34 weeks. This may be related to our earlier enrollment of infants, starting at average age of 13 hours vs the enrollment age of 3 days in the study by Amin et al. 18 Our Kd values were obtained before intralipid infusion, when bilirubin-albumin binding was dependent only on TSB and Kd, not on displacement by FFAu.
A unique feature of this study is the sensitive measurement of FFAu, the portion of FFA not bound to albumin. For healthy adults, mean concentrations of FFAu in serum are about 1.5 nM, and even with severe physiologic insults FFAu rarely rise above 10 nM. 19 Moreover, FFAu levels generally are consistent in adults in the fasting or postprandial state because FFA produced by hydrolysis of serum triglycerides are rapidly taken up by adipose, muscle and liver tissue. 20 This finding suggests that the high levels of FFAu in the infants treated with intralipid are due to robust lipase activity and/or severely reduced FFAu uptake and metabolism. As the result of these developmental phenomena, infants may not receive the full nutritional benefit of intralipid and may in fact be at risk for FFAumediated toxicity. This observation is of clinical importance because weight gain in infants with extremely low birth weight is related directly to improved neurodevelopmental outcome at 2 years. 21 Because of these findings, clinicians rightly are aggressive in providing high energy intake by the use of greater dose of intralipid, a high caloric density nutrient during parenteral nutrition. Our findings of high probability of generating a high FFAu and Bf require a reassessment of this nutritional strategy to balance the benefits of nutritional value and the potential risk of bilirubin neurotoxicity. Furthermore, at high levels, FFAu are physiologically active, potentially inhibiting immune activity and exerting cardiotoxicity. 19, 22 Our finding that Bf and TSB are uncoupled at standard doses of intralipid infusion (2-3 g/kg/d) highlights a potential concern for clinicians, especially during phototherapy. The effectiveness of phototherapy, which converts TSB into water-soluble isomers that bypass hepatic conjugation to be excreted without further metabolism, 23 is judged presently by its impact on TSB with the assumption that there is direct correlation between TSB and Bf. Our data, however, show that when infants also are receiving high doses of intralipid (2-3 g/kg/d) there is no correlation between TSB and Bf, such that Bf is unchanged in infants of <28 weeks of gestation ( Table I) . The reason for the lack of reduction of Bf may be due to a combination of a greater level of FFAu and lower bilirubin-albumin binding capacity and/or affinity in this population.
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A recent study by the Neonatal Research Network highlighted the danger of using TSB to guide therapy, showing that aggressive phototherapy reduced neurologic deficits but increased the rate of death in infants with extremely low birth weight. 2 Not considered in this investigation was the possibility that FFAu derived from intralipid, which almost all infants with extremely low birth weight receive during the first week of life, displaced albumin-bound bilirubin and subjected infants to bilirubin toxicity. 3 Our own previous study suggested that increases in FFAu and Bf can reach extreme and toxic levels, and that under such conditions phototherapy cannot reduce Bf sufficiently. 12 This investigation was not aimed at documenting the short-or long-term toxicity of elevated Bf levels; thus, auditory brainstem responses in the infants were not collected. 6 The standard of care in our neonatal intensive care unit is a hearing test by an automated auditory brainstem response test that provides only pass/fail data and infants who fail this screen are referred to the audiology program, where the workup may include a diagnostic auditory brainstemevoked response test.
In summary, increasing dose of intralipid infusion results in increase in FFAu and Bf, the latter independent of TSB. In infants born extremely preterm (gestation <28 weeks) receiving high-dose (2-3 g/kg/d) administration, phototherapy reduces TSB but not Bf. ■ 
